Back to Search
Start Over
Pharmacogenomics: a tool to prevent and cure coronary heart disease.
- Source :
-
Current pharmaceutical design [Curr Pharm Des] 2007; Vol. 13 (36), pp. 3726-34. - Publication Year :
- 2007
-
Abstract
- Inflammation and genetics play an important role in the pathogenesis of coronary heart disease (CHD). This is supported by epidemiological studies which have thoroughly investigated the association between CHD and gene polymorphisms of the inflammatory molecules. Moreover, efforts to find elective therapy have not been rewarding and, despite the increasing appreciation of the role of genetics in CHD and myocardial infarction (MI) pathogenesis, pharmacogenomic approaches to uncover drug target have not been extensively explored. A critical search of published literature has suggested few inflammatory genes directly involved in the risk to develop CHD and MI. The selected genes are, the pro- and anti-inflammatory cytokines, Toll-like receptor 4 (TLR4), CD14, CCR5, cyclooxygenases (COXs) and lipoxygenases (LOXs). The associations between candidate gene polymorphisms and CHD/MI are difficult and complex as a consequence of pleiotropy, variations with age, selection due to the lethality of the disease, and interactions with other genes and environmental factors. However, current data indicate that screening for interleukin (IL)-6, IL-10, TLR4, CCR5, COX and LOX polymorphisms are likely to be a useful tool for CHD and MI risk assessment. What we believe is that dissecting out the influence of genetics polymorphism within the complex pathophysiology of CHD and MI will help to provide a more complete risk assessment and complement known classical cardiological risk factors. The detection of a risk profile will potentially allow both the early identification of individuals susceptible to disease and the possible discovery of potential targets for drug of lifestyle modification.
- Subjects :
- Atherosclerosis complications
Atherosclerosis therapy
Case-Control Studies
Chemokines genetics
Coronary Disease prevention & control
Cytokines genetics
Genetic Predisposition to Disease
Humans
Inflammation complications
Inflammation therapy
Lipopolysaccharide Receptors genetics
Lipoxygenase genetics
Myocardial Infarction genetics
Myocardial Infarction therapy
Prostaglandin-Endoperoxide Synthases genetics
Receptors, Chemokine genetics
Risk Assessment
Risk Factors
Toll-Like Receptor 4 genetics
Treatment Outcome
Atherosclerosis genetics
Coronary Disease genetics
Coronary Disease therapy
Inflammation genetics
Patient Selection
Pharmacogenetics
Polymorphism, Genetic
Subjects
Details
- Language :
- English
- ISSN :
- 1873-4286
- Volume :
- 13
- Issue :
- 36
- Database :
- MEDLINE
- Journal :
- Current pharmaceutical design
- Publication Type :
- Academic Journal
- Accession number :
- 18220812
- Full Text :
- https://doi.org/10.2174/138161207783018617